{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:29Z","timestamp":1789614149930,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019402","name":"Puma Biotechnology Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"The Susan G Komen Breast Cancer Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000142","name":"Avon Products Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"The Breast Cancer Research Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017088","name":"Translational Breast Cancer Research Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104881","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:48:25Z","timestamp":1784537305000},"page":"104881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-9627","authenticated-orcid":false,"given":"Thomas","family":"Grinda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-3487","authenticated-orcid":false,"given":"Hillary M.","family":"Heiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-167X","authenticated-orcid":false,"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raechel","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"DeMeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar A.","family":"Santa-Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Van Poznak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-7960","authenticated-orcid":false,"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-4667","authenticated-orcid":false,"given":"Michelle E.","family":"Melisko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-9800","authenticated-orcid":false,"given":"Ciara C.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9646-1260","authenticated-orcid":false,"given":"Claudine","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn T.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Savoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio C.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4284-5656","authenticated-orcid":false,"given":"Mothaffar F.","family":"Rimawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Rocque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-5944","authenticated-orcid":false,"given":"Ian E.","family":"Krop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-5413","authenticated-orcid":false,"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104881_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.breast.2026.104881_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104881_bib3","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PS11-01","article-title":"Abstract PS11-01: brain metastases in metastatic breast cancer: prevalence per line of treatment and cumulative incidence in a cohort of 18075 real-world patients","volume":"84","author":"Sammons","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104881_bib4","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104881_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-024-01286-1","article-title":"Central nervous system metastases in breast cancer","volume":"26","author":"Grinda","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.breast.2026.104881_bib6","first-page":"945","article-title":"Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2\u2013Positive breast cancer and brain metastases","volume":"34","author":"Freedman","year":"2016","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.breast.2026.104881_bib7","first-page":"1081","article-title":"Tbcrc 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2\u2013Positive breast cancer and brain metastases","volume":"37","author":"Freedman","year":"2019","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.breast.2026.104881_bib8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","article-title":"Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational breast cancer research consortium trial 022","volume":"35","author":"Freedman","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104881_bib9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/neuonc\/noad169","article-title":"NCCN CNS tumor guidelines update for 2023","volume":"25","author":"Nabors","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.breast.2026.104881_bib10","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-PD7-03","article-title":"Abstract PD7-03: translational breast cancer research consortium trial 022: neratinib and trastuzumab-emtansine for HER2+ breast cancer brain metastases (BCBM)","volume":"83","author":"Freedman","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104881_bib11","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.annonc.2020.05.012","article-title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","volume":"31","author":"Barcenas","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104881_bib12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/cncr.32615","article-title":"Patient-reported outcomes in the translational breast cancer research consortium","volume":"126","author":"Bowen","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2026.104881_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438512","article-title":"Integrating patient-reported outcomes into the care of people with advanced cancer\u2014A practical guide","volume":"44","author":"Lai-Kwon","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.breast.2026.104881_bib14","first-page":"3669","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.breast.2026.104881_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.24793","article-title":"Patient-reported outcome measures in cancer care: an updated systematic review and meta-analysis","volume":"7","author":"Balitsky","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2026.104881_bib16","first-page":"548","article-title":"Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial","volume":"37","author":"Barcenas","year":"2019","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.breast.2026.104881_bib17","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/ajg.2014.237","article-title":"Development of the NIH patient-reported outcomes measurement information system (PROMIS) gastrointestinal symptom scales","volume":"109","author":"Spiegel","year":"2014","journal-title":"Official Journal of the American College of Gastroenterology | ACG"},{"key":"10.1016\/j.breast.2026.104881_bib18","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s10620-017-4499-9","article-title":"Responsiveness to change and minimally important differences of the patient-reported outcomes measurement information system gastrointestinal symptoms scales","volume":"62","author":"Khanna","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.breast.2026.104881_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12955-017-0794-6","article-title":"Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients","volume":"15","author":"Lui","year":"2017","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.breast.2026.104881_bib20","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst: J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104881_bib21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clin Trials"},{"key":"10.1016\/j.breast.2026.104881_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13058-024-01823-8","article-title":"Nsabp FB-10: a phase Ib\/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer","volume":"26","author":"Jacobs","year":"2024","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2026.104881_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104881_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.breast.2022.12.003","article-title":"Final findings from the CONTROL trial: strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer","volume":"67","author":"Chan","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104881_bib25","first-page":"536","article-title":"Dose escalation for mitigating diarrhea: ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer","volume":"39","author":"Marx","year":"2021","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.breast.2026.104881_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100475","article-title":"Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer","volume":"7","author":"Modi","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104881_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114313","article-title":"Improving completion rates of patient-reported outcome measures in cancer clinical trials: scoping review investigating the implications for trial designs","volume":"212","author":"Van der Weijst","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:26:14Z","timestamp":1789611974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"alternative-id":["S0960977626001918"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104881","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104881"}}